Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of PDI204 as Intravenous Infusion or Intramuscular Injection in Healthy Participants

NCT06965751 is registered in ClinicalTrials.gov with University of Melbourne as lead sponsor.

NCT NCT06965751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06965751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of PDI204 as Intravenous Infusion or Intramuscular Injection in Healthy Participants
Lead sponsor
University of Melbourne
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 27, 2025
Completion date
August 31, 2026
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 infection